The Emergent Group

Emergent BioSolutions is a global life sciences company that develops and manufactures medical countermeasures for public health threats, including biological warfare agents and emerging infectious diseases. The company is widely recognized for its commercial portfolio, which features Narcan (naloxone) nasal spray for opioid overdose reversal and the anthrax vaccine BioThrax. Emergent also serves as a major contract development and manufacturing organization (CDMO), providing services to government agencies and pharmaceutical partners. Headquartered in Gaithersburg, Maryland, the company plays a critical role in the U.S. Strategic National Stockpile and global health security infrastructure. In 2023, the company underwent a strategic realignment to focus on its core biodefense and commercial public health products while divesting its travel health business.